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ABSTRACT 
 
Full Name : Mohammed Yagoub Ahmed Jomaa 
Thesis Title : Synthesis and characterization of some thione containing platinum(II) 
complexes and their  anticancer activity  
Major Field : Chemistry  
Date of Degree : May 2015 
 
Cisplatin is one of the well-known anti-cancer agents it has been used for decades in cancer 
therapy. However, it has severe side effects. Therefore, it is desirable to design new 
platinum(II) complexes that would be able to enlarge the biological activity spectrum, 
improve clinical effectiveness as well as reduced toxicity. A new series of platinum(II) 
complexes based on thione ligands with general formula, cis-[(Et3P)2Pt(L)2]Cl2, cis-
[(NH3)2Pt(L)2](NO3)2,  trans-[Pt(NH3)2(L)2](NO3)2 and [Pt(iPrImt)4](NO3)2(H2O)0.6 have 
been synthesized and characterized using CHNS elemental analysis, mid- and far-IR, 1H 
and 13C solution NMR as well as 13C solid-state NMR spectroscopy, and X-ray 
crystallography. The spectroscopic methods reveal that the Pt(II) center coordinates to 
thione ligands via sulfur donor atoms. The X-ray structures showed a distorted square 
planar geometry for trans-[Pt(NH3)2(Imt)2](NO3)2 and trans-[Pt(NH3)2(Me2Imt)2](NO3)2 
complexes (T1 and T3), while hydrogen bonding interactions in 
[Pt(iPrImt)4](NO3)2.0.6(H2O) complex induce a see-saw distortion relative to the ideal 
square planar geometry. In vitro cytotoxicity studies of complexes (A1-A7) on four 
different cell lines (Hela, A549, MCF7 and HCT15) are promising and make these 
complexes potential anticancer agents. Complex A6 was found to be the best and 14 fold 
better cytotoxic agent than cisplatin against human colon cancer cell line (HCT15). 
 vx
 
 ملخص الرسالة
 محمد يعقوب احمد جمعه :الاسم الكامل 
 ) مع بعض مترابطات الثايون ونشاطيتها كمضادات للسرطانIIتخليق وتوصيف معقدات البلاتين(: عنوان الرسالة 
 كيمياء :التخصص 
 5102مايو  :تاريخ الدرجة العلمية 
لسرطان وقد تم استخدامه منذ عقود في علاج السرطان. ومع ذلك له عدة احدة من العقارات المشهورة ضد اسيسبلاتن و
تكون لها القدرة على توسيع طيف النشاط  )II(اثارة جانبيه. لذلك، من المستحسن تخليق معقدات جديدة للبلاتين
مع بعض مترابطات  )II(خفض السميه. سلاسل جديدة من معقدات البلاتينوالبيولوجي، تحسين الفعاليه السريريه 
   snart-   ، sic-HN([3)2)L(tP2ON(]3)2  ،sic-tE([3)P2)L(tP2lC]2الثايون تم تخليقها بالصيغ العامه 
، ها باستخدام تقنيه تحليل العناصرفيوصتوتم  (tPi)tmIrP4ON(]3)2H(2)O6.0 و HN(tP[3)2)L(2ON(]3)2
)، وكذلك 1 ,H31 ,C13P(كل من  الرنين النووي المغناطيسي لانويه، ه تحت الحمراء المتوسطه والبعيدةمطيايفيه الاشع
 بالاضافه الى الاشعه السينيه للبلورات.  )31Cالرنين النووي المغناطيسي في الحاله الصلبه لنواة (
) عبر ذرة الكبريت المانحه. IIاظهرت ان مترابطات الثايون مرتبطه بالايون المركزي للبلاتين( التحليل الطيفيطرق 
التعرف على البنيه التركيبيه لبعض المركبات، حيث اظهرت ان  تم استخدام طيف الاشعه السينيه للبلورات ب
  ) T1و T3 (  snart-HN(tP[3)2eM(2)tmI2ON(]3) 2و  snart-HN(tP[3)2)tmI(2ON(]3) 2      المعقدين 
 (tP[i)tmIrP4ON(]3)2H(6.0.2)Oي المعقد الرابطه الهيدروجينه فا تفاعلات لها شكل رباعي سطوح مشوه، بينم
 ي لرباعي السطوح.مقارنه بالشكل المثالوجود تشويه الارجوحه  حثت 
خطوط مختلفه من الخلايا البشريه (خليه سرطان عنق الحم،  على اربعه 7A-1Aدراسه الفعاليه الحيويه للمركبات 
خليه سرطان الرئه، خليه سرطان الثدي وخليه سرطان القولون)، اظهرت نتائج واعدة مما جعل هذه المركبات محتمله 
 كمضادات للسرطان.
ضد خليه سرطان القولون البشري تين ف السيسبلااضعا 41وجد انه الافضل بين المركبات وله فعاليه حيويه  6Aالمعقد 
).51TCH(
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1 CHAPTER 1 
INTRODUCTION 
Bioinorganic chemistry is a  rapidly developing area of research with enormous potential 
applications in medicine [1]. Different metal complexes are presently used to treat  various 
types of human disorders [2]. cis-Diammine dichlorido platinum(II) complex, clinically 
called cisplatin, is one of the most effective anticancer agent [3–5], showed  a broad 
spectrum and high level of activity in the history of  a successful antitumor drug [6–8]. It 
is generally believed that the biological activity of this drug results from its interactions 
with DNA [9]. It has been used for cancer treatment for the last forty years [10], particularly 
in treating specific cancers, including  small and  non-small cell lung, ovarian, testicular, 
head, neck and bladder tumors [11, 12]. 
Despite its great success and wide spectrum of applications [13], unfortunately, cisplatin is 
not effective against some cancer cells. In addition, this drug has several toxic side effects, 
like nephrotoxicity, neurotoxicity, ototoxicity and emetogenesis [14–16], and also limited 
by inherent and acquired tumor resistance [17].  In response to the urgent need for new 
anti-cancer drugs that are capable to overcome these disadvantages, thousands of Pt(II) 
complexes have been developed [18]. Researchers synthesized cisplatin analogues. 
However, a few of the developed  compounds have entered human clinical testing, for 
instance  carboplatin, which received worldwide registration for clinical use, while others 
received limited approval, such as oxaliplatin, in some countries, nedaplatin, lobaplatin, 
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and heptaplatin in Asia,  China, Japan and South Korea, respectively [5, 11]. However, 
since most of these compounds have a common structure as cisplatin, the presence of two 
good leaving groups and two ammine ligand or two amine donor groups in cis 
configuration, this produce similar adducts with DNA as cisplatin and some drawbacks 
associated with cisplatin are consequently inherited [19]. 
A logical strategy has been directed toward the design of new Pt(II) complexes which 
interact distinctively in a different manner with DNA. One platinum agent that is known to 
possess DNA binding mode different from those of cisplatin is the trans isomer [20], While 
it’s thought that the two good leaving groups in cis geometry in the Pt(II) complexes are 
necessary for the cytotoxic activity, some exceptional cases have been reported recently, 
where some trans isomers  with planar heterocyclic ligands [21], are able to exhibit higher 
anticancer activity against cisplatin resistant cancer cells [12].  
1.1  Statement of the problem 
After administration of cisplatin in the human body there are many possibilities for binding, 
wither interaction of Pt(II) ion with the sulfur containing ligand biomolecules in  the form 
of proteins, enzymes and  peptides,  such as glutathione (GSH) and L-cysteine, in 
intracellular, or  with nitrogen containing biomolecules such as amino acids or DNA. 
The cytotoxicity of the Pt(II) complexes is generally attributed to the interaction of the 
platinum metal with nitrogen donor biomolecules in DNA [22]. On the other hand Pt(II) 
compounds can interact with sulfur donor biomolecules before they reach the DNA, to 
form Pt-thiol complexes which are thermodynamically stable. These are believed to be  
responsible of the toxicity occurrence [23]. 
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1.2    Rationale of the current study 
The interaction of Pt-S(thiol) can be avoided using some ligands known as rescue  or 
protecting agents, which are compounds containing sulfur and they are very strong 
nucleophiles. These compounds have been used to control the toxicity of cisplatin, such as 
thiourea, thiosulfate, diethyldithiocarbamate, thiosemicarbazone, xanthate, cysteine, GSH, 
etc. [24]. Pt(II) compounds coordinated to sulfur-containing ligands and possessing similar 
structures to cisplatin, have demonstrated  superior or equal effectiveness against  some 
human cancer cell lines and with less toxicity effect than cisplatin [25], The coordination 
of platinum with thiourea and its derivatives has been known for a long time, even though 
initial interest of these complexes were not related to their biological activities [26].  
The high activity of platinum compounds with sulfur-donor ligands toward some cancer 
cells encouraged us to prepare some thiones containing platinum(II) complexes. Therefore 
the synthesis of complexes and studying their cytotoxic effect represents an interesting area 
of research. Specifically the aims of this work is to synthesize and characterize some thione 
containing platinum(II) complexes in order to produce non-cisplatin behavior.  
In general, thiones are a class of organosulfur ligands [27]. Thione ligands used in this 
work were prepared according to the reported procedure by the addition of carbon disulfide 
to diamines in ethyl ether, the resulting adduct was heated, at 100-110 ºC for 2-3 hours, 
then crystallized in methanol [28]. The general structures of sulfur-donor ligands (Thiones) 
used in this work are given in, (Fig 1.1).  
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1 R = R/ = H; Imidazolidine-2-thione (Imt). 
 2    R = CH3, R/ = H; N-methylimidazolidine-2-thione (MeImt). 
 3    R = C3H7, R
/ = H; N-propylimidazolidine-2-thione (PrImt). 
 4    R = i-C3H7, R
/ = H; N-(i-propyl) imidazolidine-2-thione (i-PrImt). 
 5    R = R/ = i-C3H7; N N
/-(dii-propyl)imidazolidine-2-thione (dii-PrImt). 
 6    R = R/ = CH3; N,N
/-dimethylimidazolidine-2-thione (Me2Imt). 
7 R = R/ = C2H5; N, N/-diethylimidazolidine-2-thione (Et2Imt). 
8 R = H; 1,3-Diazinane-2-thione (Diaz). 
9 R = C2H5; N-ethyl-1,3-Diazinane-2-thione (EtDiaz). 
10 1, 3-Diazipane-2-thione (Diap). 
Figure 1.1 General structures of sulfur-donor ligands (thiones) used in this work 
 
1.3   Objectives 
The objectives of this work are as follow. 
a. Synthesis of complexes with general formula cis-[(NH3)2PtL2](NO3)2 by using  cis-
[(NH3)2PtCl2] and a series of thione ligands as precursors. 
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b. Synthesis of complexes with general formula trans-[(NH3)2PtL2](NO3)2 based on  cis-
[(NH3)2PtCl2] and a series of thione ligands. 
c. Synthesis of complexes with general formula cis-[(Et3P)2PtL2](NO3)2 by using  the cis-
[(Et3P)2PtCl2] and a series of thione ligands. 
d. Characterization of  the synthesized complexes by different techniques like elemental 
analysis, FT-IR spectroscopy, 1H & 13C solution NMR, and 13C solid state NMR 
spectroscopy in addition to single-crystal X-ray crystallography. 
e. In vitro anticancer activity studies of the synthesized complexes against a panel of 
human cancer cell lines. 
1.4  The thesis organization 
The work in this thesis has been divided into five main chapters 
1.4.1   Chapter one: introduction 
A brief introduction is given about the anticancer drugs specially cisplatin and its analogues 
and their drawbacks. The problem of this study is also stated, followed by the aim and 
objectives of our work.  
1.4.2    Chapter 2: literature review 
A short review about cancers, cancer treatment, the proposed mechanism and the mode of 
action of the most successful anticancer agent cisplatin. 
1.4.3 Chapter 3: methodology and techniques 
The first part of this chapter describes the methodologies which we followed to synthesize 
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our complexes. In the second part a detailed description of the characterization techniques 
used to analyze the prepared compounds is given.  
1.4.4 Chapter 4: results and discussions 
This chapter shows the significance of our work and results from all characterization 
techniques and discussions. 
1.4.5 Chapter 5: conclusion and recommendations 
The general conclusion of the work is summarized in this chapter and describes how this 
work could be extended in the future. 
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1 CHAPTER 2 
LITERATURE REVIEW 
2.1 Cancer 
Cancer is a name for a number of many diseases in which the body cells grow abnormal 
then divide without control and easily invade other tissues. Cancer cells growth and spread 
through the blood stream and lymph systems to other parts of the body. Lastly the tumor 
load will cause death in humans [29]. Cancer presents two types of tumors, malignant 
tumors and benign tumors. Malignant tumors are different from benign tumors as they 
show uncontrollable growth, invade locally, and metastasize to distant body parts, they are 
named according to the type of cell or organ in which they start such as breast cancer, lung 
cancer, colon cancer, etc. Benign tumors grow in one place and lack the ability to 
metastasize [30].  
Cancer is caused by both internal factors such as hormones, inherited mutations and 
immune conditions or acquired/environmental factors such as radiation, diet, tobacco, 
infectious organisms [31]. 
2.2 Cancer treatment 
There are many methods used for cancer treatment, it can be used alone or in combination, 
including surgery, biological therapy, immunotherapy, radiation, gene therapy and 
chemotherapy[32]. 
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2.2.1 Surgery 
In this case cancer can be surgically removed from the body and lead to a complete cure. 
This treatment is often used in the removal of the breast, testicle or prostate. However, it is 
almost impossible to remove all of the cancer cells after the disease has spread. Surgery 
can be also by instrumental in helping to control symptoms such as spinal cord compression 
or bowel obstruction [33]. 
2.2.2 Radiotherapy 
 High energy rays, such as gamma rays that are emitted from metals like radium or energy 
that can be generated from special machines such as X-ray are used or exposing on the 
cancer cells. These rays cause damage to the molecules that make the cancer cells and lead 
them to destroy oneself. The energy beams cannot differentiate between normal tissues and 
carcinogenic tissues this will lead to severe side effect, but technological improvements 
have been made so the carcinogenic tissues can be targeted accurately. This type of 
treatment can be  used alone or in combination with other treatment methods [33].  
2.2.3 Immunotherapy 
This method of treatment is aiming to get the body’s immune system to fight the cancer. 
Materials either made by the body or in a laboratory are used to restore or improve the 
immune system function. Although the mechanism of immunotherapy that treats cancer is 
still not well understood, it may work by slowing or stopping the cancer cell growth, 
stopping cancer from spreading all over the body, or helping the immune system to increase 
its effectiveness at eliminating cancer cells [34].  
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2.2.4 Gene therapy 
Gene therapy is designed to remove the roots that cause cancer by replacing the damaged 
genes with ones that work. Many research works have been carried out to replace the 
damaged genes that signals cells to stop dividing with a copy of a working gene [35]. 
2.2.5 Chemotherapy 
Chemotherapy is a type of treatment that uses chemical compounds to damage the cells 
that are rapidly dividing mainly cancer cells, so chemist can play an important role. 
Extensive research has been done to develop potent chemotherapeutic agents [32]. Since 
the drugs travel throughout the entire body, chemotherapy is suitable to treat cancers that 
have spread or metastasized. The treatment occurs in cycles, so the body has time to heal 
between doses [36]. However, there are common side effects such as hair loss, nausea, 
vomiting, and fatigue [37]. Chemotherapy often includes multiple drugs in combination, 
or it can be also used in combination with another type of  treatment [36]. 
2.3 Non-metal containing cancer drugs 
The therapeutic properties of natural products have been used for a long time, the practice 
is as ancient as human civilization. Natural products have provided all humankind needs 
in term of food, clothing, shelter, flavors and perfumes and it’s the source of most drugs in 
medicine, and most of these therapeutic agents are provided by the higher plants [38]. 
Nowadays, natural products, derivatives and their analogues are commonly used as 
curatives and represents more than 50% of all drugs in the medicinal use worldwide, with 
higher plant-derived natural products representing approximately 25% of the total [38]. A 
major group of these products includes the powerful antioxidants, others are phenolic in 
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nature, and some important drugs that obtained from plants like quinine and quinidine from 
Cinchona spp., Digoxin from Digitalis spp., Vinblastine and vincristine from Catharanthus 
roseus, codeine and morphine from Papaver, atropine from Atropa belladonna and 
somniferum. [39]. It is estimated that about 60% of antitumor and  anti-infective drugs that 
are available on the market or in the clinical testing’s are of natural origin [40]. Besides the 
natural products that exhibit anticancer activity such as tamoxifen (Nolvadex) paclitaxel 
(Abraxane or Taxol), vincristine (Oncovin),  Podophyllotoxin (Condylox) and 
camptothecin  [41], there are many others that have served as templates or chemical models 
for the synthesis, semi-synthesis, and design of novel substances for diseases treatment 
[42].   
 
 
 
 
 
 
 
 
Figure 2.1 Structures of compounds among the clinically useful drugs 
Camptothecin 
Podophyllotoxin Vincristine 
Taxol 
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 It’s worth mentioning that metal-containing drugs (inorganic based drugs) still remain 
superior to other agent’s especially anticancer drugs. This is due to the simple reason that 
inorganic compounds are synthesized with specific designs for specific targets, as to bind 
to the DNA; hence their activity as anti-cancer drugs [43]. While, the organic compounds 
are found in nature in smaller quantities and their synthesis in the laboratory is a big 
challenge, i.e. Total synthesis of taxol took many years [44].  Even though these drugs can 
be easily achieved by synthesis of other new metal containing compounds [43]. 
2.4 Metal and transition metals in medicine 
Metal ions are very important for many critical functions in humans. Deficiency of some 
metal ions can cause a disease. For examples iron deficiency causing pernicious anemia, 
growth retardation emerging from insufficient dietary zinc, and heart disease in infants due 
to deficiency of copper. Furthermore, metal ions may also induce toxicity in humans, heavy 
metal poisons such as lead and mercury being classic examples. Even that are essential can 
be toxic when present in excess [45]. Some metal complexes showed activity against some 
human disease such as, Ga3+, Al3+ and Fe3+ were shown to have activity against malaria 
[46].  
Transition metal complexes have been widely used in medicine as drugs for treating several 
human diseases, such as carcinomas, antiarthritis, anti-inflammatory, infection control, 
diabetes,  lymphomas, and neurological disorders [47]. Transition metals exhibit unique 
properties like electrophilicity, Lewis acidity, redox activity, valency, magnetic resonance 
and radiochemical properties, and can covalently interact with a negatively charged 
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molecules. Transition metal-based drugs have promising medicinal applications , some has 
shown unique therapeutic activities [48].  
In the early 1960s the anticancer activity of Pt(II) complex, cisplatin, one of the most 
effective and widely used cytotoxic drug was discovered, other metals such as gold, 
titanium, ruthenium, and vanadium also showed promising results in this area [49]. One of 
the interest metal in cancer therapy is silver because its toxicity level in humans is believed 
to be quite low. Silver is being used in medical applications, including cardiac catheters, 
coating of heart valves, and urinary catheters to  prevent or reduce infection [50]. It is 
widely known that excessive exposure to silver for long periods causes Argyria, which is 
permanent skin discoloration [50]. 
In the early 1970’s rhodium was discovered to possess antitumor activity against various 
tumor cell lines, the majority of the rhodium complexes evaluated were found to be active 
but they are highly toxic and have lesser effectiveness than cisplatin. A class of dirhodium 
compounds [µ-(RCO2)4Rh2(H2O)2] (R: Alkyl group), in particular, displayed high activity 
in vivo against many types of tumor, however; several toxic side effects hindered their 
advancement. Ruthenium complexes were also reported for their antitumor activity. The 
earliest investigation of ruthenium compounds having antitumor activity discover when 
Clarke investigated the activity of fac-[Ru(III)Cl3(NH3)3] in the 1980’s. However this drug 
has a poor water solubility. Up to now there are  many of ruthenium compounds have been 
investigated, but, only a few of them have activity comparable to cisplatin [51]. 
Copper is an essential trace element and that plays a vital role in the biochemistry of every 
living organism. The use of copper in cancer treatment was reported in the early 1980s on 
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the activity of copper thiosemicarbazones. Recently copper complexes of carboxylates and 
carboxamidrazones have been developed [52].  
Rhenium has also potential applications in the field of cancer treatment. Re(IV)-based 
complexes of the type [ReCl4(L)] have shown potent anti-proliferative effects in vitro 
against some cancer cell lines. These complexes represent novel, potentially active metallo-
drugs based on  the satisfactory results [53].  
Metallic gold and gold complexes, have been used for a long time in medicine [47]. The 
value of gold in this field was recognized when the bacteriologist Koch’s explored the 
activity of K[Au(CN)2] in fighting the bacteria that cause tuberculosis, it was used to treat  
rheumatoid arthritis, which they believed was related to tuberculosis. gold(I) with 
phosphine as ligands that can stabilize the +1 oxidation state attract much attention, many 
gold(I) phosphine compounds have been evaluated, such as triethylphosphine compounds 
and auranofin, were found  to possess excellent activity for rheumatoid arthritis treatment 
[54].  
2.5 Platinum based anticancer drugs 
Platinum compounds are well known as successful chemotherapeutic agents such as 
cisplatin, which indicated considerable activity toward some of the cancer cell lines. It was 
first synthesized in 1844 by Michel Peyrone and called Peyrone chloride at that time [55]. 
In 1893 Alfred Warrner deduced the structure of cisplatin. Its biological activity was 
discovered accidentally in the 1960s by Barnett Rosenberg in United States at University 
of Michigan, East Lansing [56]. Initially, he designed to study whether magnetic or electric 
dipole fields contribute to cell division, by applying electromagnetic radiation on 
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mammalian and bacterial cells. Without intention, a set of platinum electrodes which is 
known to be inert was involved in the growth chamber of Escherichia coli in ammonium 
chloride buffer [18]. After the electromagnetic field turned on, the filamenation occurs 
which is a strange growth of the bacteria length; reached up to 300 times of the normal 
length. This phenomenon could not be attributed to the effect of the applied field. 
Investigations found that the observation is due to the presence of platinum(II) and 
platinum(IV) ammine chlorido complexes formed in situ originating from electrolysis at 
the platinum electrodes. Further investigations showed that specifically, cis-diammine 
dichlorido platinum(II) is the causing molecule of these biological effects [57]. 
Several medicinal trials of cisplatin as a drug commenced soon thereafter, and it was used 
to treat the first patient in 1971. Cisplatin was granted approval against several human 
cancers in 1978  by the US food and drug administration (FDA) [7]. At present, cisplatin 
is considered to be one of the most extensively used anticancer drugs [5, 58]. This is due 
to its activity against a lot of cancer cells like bladder, cervical, ovarian, head and neck, 
 
Figure 2.2 Cell division and bacteria filamentation 
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testicular, small-cell and non-small cell lung cancers. In spite of the mentioned, cisplatin 
is ineffective in other cancers e.g. Leukemia, gastrointestinal, and renal cancers [3]. 
Generally it was believed that the relationship between structure and activity of platinum 
drugs is the cis geometry. Platinum atom should bind to bidentate amine ligands or cis to 
two amines (at least have one NH group on the amine) and two good leaving groups with 
an intermediate binding strength, such as chloride, sulfate, oxalate and citrate, until Farrel 
and his group reported that platinum complexes with trans configuration are also able to 
show antitumor activity. Examples of such biologically active trans platinum compounds 
include tran-[PtCl2(iminoether)2] and trans-[PtCl2{NH2CH(CH3)2}{NH-(CH3)2}] [47].  
 
Pt
H3N
H3N Cl
Cl
                                
Pt
NH3
H3N Cl
Cl
 
Figure 2.3 Isomeric structure of diamminedichlorido platinum(II) complex 
When the two ammine ligands were replaced by a planar pyridine ligand and  trans-[PtCl2 
(py)2,] was formed, the cytotoxic effect of the new complex is dramatically enhanced 
compared to that of both  cisplatin and transplatin isomers [59]. 
2.5.1 The mechanism of action of cisplatin 
After administration of cisplatin usually intravenously through injection, although there is 
some evidence that uptake may occur by an active transport mechanism,  a variety of 
chemical reactions may take place [60].   
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It’s generally accepted that the neutrality of cisplatin allows it to enter the cell through 
passive diffusion, due to the fact that the concentration of chloride ion inside the cell is 
relatively low, approximately 3–20 mM compared to the extracellular medium, 
approximately 100 mM.  It has to be activated through spontaneous aquation reactions [61], 
which involve the replacement of one chlorido ligand by water molecule to form of reactive 
monoaqua adduct or by replacement of the both chlorido ligands and form a diaqua 
complex. These aquated species are highly active due to positive charge and H2O molecule 
is a better leaving group than Cl-, these species can react with  many different cellular 
targets, including proteins, glutathione or others inside the cell [62]. 
 
Figure 2.4 Cellular uptake of cisplatin drug 
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2.5.2   Interaction of cisplatin with DNA targets 
It’s widely  believed that the cytotoxicity of CDDP is due to the formation of DNA adducts 
to induce its significant biological effects, either repair the damage of the DNA and cell 
survival or activation of the irreversible apoptotic program [63, 64]. Although many 
components have electron lone pairs in the DNA, where metal ions may covalently bind 
(i.e. The phosphate groups, the sugar, oxygen atoms, and the heterocyclic nucleobases), 
early investigations showed  that N7 position in the imidazole rings of both guanine and 
adenine are the most accessible and reactive site for platination due to their high 
Figure 2.5 Spontaneous hydrolysis of cisplatin in aqueous solutions 
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nucleophilicity [60]. Platination may form  different DNA adducts such as monofunctional 
cis-[Pt(NH3)2(H2O)]-DNA, bifunctional cis-[Pt(NH3)2]-DNA called intrastrand  or 
interstrand cross-links [65]. It was found that 60 - 65% of the formed adducts are 1, 2-
d(GpG) intrastrand cross-links binding with  two neighboring guanine in the same strand   
and 20 - 25% d(ApG) cross-links with one adenine and one guanine [9, 66]. It was shown 
that minor adducts 1, 3-d(GpTpG) intrastrand and interstrand cross-link with two guanine 
separated by one nucleotide  could be also involved in the mechanism of action of cisplatin, 
and  DNA-protein cross-links have also been reported to be induced by cisplatin [67], 
However, consequently,  these cross-links mainly 1, 2-d(GpG) intrastrand  lead to either 
cell repair by removing the adduct or cell destrotion by preventing the replication of the 
DNA . The mechanism by which these adducts lead to the significant biological effect is 
not well understood [67]. 
 
Figure 2.6 Different cisplatin - DNA binding ways 
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2.5.2.1 Guanine versus adenine 
It’s believed that the N7 atoms of the imidazole rings in the DNA purine bases guanine and 
adenine are most nucleophic and accessible sites which can be a major target for 
platination, mainly through 1, 2-d(GpG) or  1,2-d(ApG) intrastrand cross-links. It was 
found that N7 of guanine is thermodynamically  and kinetically favorable site for binding 
over adenine  that leads to bending and unwinding of DNA [10, 12]. 
After the binding of platinum to the nucleophilic site in both structures, the ammine ligands 
act as hydrogen-bond donors, whereas C6 position in the guanine ring (oxo group) and 
(amino group) in case of adenine ring, known to be  hydrogen-bond acceptors. The 
hydrogen bond between the N-H….O=C6 in case of guanine is a much stronger than the 
hydrogen bond forms between the N-H….NH2-C6 in case of adenine. In addition, MO 
calculation have  identified strong interaction  for guanine compared to adenine [10]. 
Figure 2.7 Hydrogen bonding in case of guanine and adenine after platination 
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In order to confirm that the N7 of guanine is a preferable site for platination over adenine, 
Lippard and his group performed DFT studies of [Pt(NH3)2]
2+ complexes with guanine and 
adenine. Thermodynamics and kinetics factors of the complexes were taken into account, 
verifying that guanine is more reactive 20 times than adenine toward platination [12]. 
2.5.2.2 DNA repair 
DNA repair systems are vital to the survival of all organisms, and can be by four major 
pathways, including nucleotide-excision repair (NER), base-excision repair (BER), 
mismatch repair (MMR) and double-strand-break repair, NER is the major pathway which 
is an ATP-dependent multiprotein complex can recognize the bending that induced on 
DNA by 1, 2-intrastrand cross-links, and thereafter eliminate the cisplatin lesions from 
DNA. And then filled the gap that remains by DNA polymerase [63]. 
2.5.2.3 Tumor resistance to cisplatin  
One of the common drawbacks of platinum drugs, occurrence of the drug resistance, 
moreover, the resistance of cisplatin considerably varies between tumor types. Some 
tumors, like head and neck cancer, ovarian cancer, and small cell lung cancer, developed 
Figure 2.8 The steps involved in the repair of the major cisplatin crosslink by the NER. 
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acquired resistance. While others, such as colorectal cancer and non-small cell lung cancer 
have developed intrinsic resistance to cisplatin chemotherapy [67].  
In most preclinical models of cisplatin resistance (either intrinsic or acquired), two 
mechanisms are mediated to operate. The first one, the failure of a sufficient amount of cis-
DDP reaching DNA as its main target and the second, a failure to achieve cell death after 
the formation of the cisplatin-DNA adduct [7]. 
The acquired resistance to cisplatin is a resistance through insufficient DNA binding, 
commonly observed over many years  that cause reduction in platinum accumulation 
compared to parental [68]. This is due to the binding of the platinum with highly abundance 
sulfur containing species such as metallothionein, and glutathione that leads up to 
detoxification and thus causing resistance to cisplatin [69, 70]. 
The intrinsic resistance to cisplatin is a resistance mediated after DNA binding, after the 
formation of platinum-DNA adducts, cellular survival (and therefore, tumor, drug 
resistance) can occur either by DNA repair or removal of these adducts, or by tolerance 
mechanisms [71].   
2.5.3 Interaction of cisplatin with Non-DNA Targets 
It is well known that the activated form of cisplatin also can bind to other biomolecules 
before accumulation in the cell [72], many components have nucleophilic sites in the 
cytoplasm e.g., cytoskeletal microfilaments, thiol-containing peptides, sulfur containing 
amino acids (cysteine, methionine) and proteins, and RNA  may react with cisplatin based 
on hard-soft principle. Pt(II) is a soft acid and has high affinity to S-donor molecules, 
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glutathione (GSH) and metallothionein (MT) are the most abundant cellular thiol that can 
strongly bind to the platinum(II) ion, this binding can associate with negative phenomena  
that can prevent the performance of these proteins and lead to the toxicity [67].  The activity 
of enzymes, receptors, and other proteins may be affected also through binding of Pt(II) 
ion to sulfur atoms of methionine and/or cysteine or nitrogen of histidine residues. The 
resulting functional protein damage may also contribute to the biochemical mechanism of 
cisplatin cytotoxicity [67]. 
2.6 Cisplatin drawbacks and side effects 
In spite of the great success of cisplatin as drug, it’s not effective against some cancer cells 
(e.g. Breast and colon), and suffers from several side effects [73], such as nephrotoxicity 
(damage of the kidney), neurotoxicity (damage nervous system), ototoxicity (hear loss) and 
emetogenesis, as well as drug resistance, which remains one of the most serious and 
challenging problems to overcome, as mentioned in (2.5.2.2) [74]. Current research and  
focuses on designing a modified version of cisplatin as new generations that interact 
differently with the targeted DNA to minimize the negative aspects coupled with cisplatin, 
and are active towards tumors, which are non-responsive to current cisplatin chemotherapy. 
Many platinum complexes are currently in clinical testing, but some of them have not yet 
demonstrated significant advantages over cisplatin[11].  
2.7 Second generation carboplatin 
cis-diammine(cyclobutane-1,1-dicarboxylato) platinum(II), (Fig 2.9) is a new generation 
known as carboplatin, it differs from the first generation cisplatin by the presence of a 
bidentate ligand (dicarboxylate) as leaving group instead the labile chlorides of the 
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cisplatin, it was first discovered in the early 1970s by Rosenberg and his group to enhance 
the performance of the first generation and to expand the range of useful anticancer activity 
[75]. It was approved in 1986 under the brand name of paraplatin as a drug. Carboplatin 
has a slower substitution rate compared to cisplatin, this feature makes it much less 
chemically reactive (ototoxic, neurotoxic, and nephrotoxic) compared to cisplatin and can 
be administrated at a higher dose than cisplatin, this prompt researchers to focus and study 
how this drug can be activated in vivo [76]. After passing through the blood, carboplatin 
shows to enter the cell via passive diffusion, although it may enter through active transport 
or via ion channels also. A study done by Osella and coworkers suggests that carboplatin 
enters the cell through a passive diffusion mechanism [77]. 
The low toxicity has been the feature that enabled carboplatin to receive worldwide clinical 
use approval. Unfortunately, it’s still active only in the same cisplatin range of tumors and 
still administered intravenously [36]. Carboplatin possesses a similar structures as cisplatin 
that can form similar DNA adducts. This will lead to the same cisplatin disadvantages. So 
the researchers focused on seeking on a new platinum compound with improved 
tolerability profiles that may overcome the side effect of the first generation. 
2.8 Third generation oxaliplatin 
[(1R, 2R)-cyclohexane-1, 2-diamine](ethanedioato-O,O')platinum(II), is a third generation 
of platinum(II) complexes  known as oxaliplatin which contain a rigid, stable bidentate 
ligand 1,2-diaminocyclohexane instead of two monodentate ammine ligands and an oxalate 
as leaving group. It was approved in 1996, under the brand name eloxatin. Inclusion of the  
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rigid moiety diaminocyclohexane was intended to contribute to a larger cytotoxicity when 
compared to the first and second generation (more damaging Pt-DNA adducts), as well as 
to overcome cross-resistance with those widely used drugs [78]. Particularly, the high 
activity of the oxaliplatin, even in cisplatin-resistant tumor models, coupled to its decreased 
toxicity, encouraged further investigations on its use as a treatment option after the failure 
of the first or second generations therapy [79]. 
 
 
2.9 Sulfur containing Ligands in the synthesis of anticancer drugs 
The properties of metal- ligand coordination in classical inorganic coordination compounds 
or in organometallic and in bioinorganic compounds, are largely determined by the nature 
of ligands bound to the metal ion [79]. Most ligands are based on sulfur containing 
heterocyclic compounds moieties such as dimethyl sulfoxide, dimethyl sulfide, and 
thiosemicarbazones and xanthate have shown a lot of pharmacological benefits [24]. 
Thiourea and its derivatives, such as 1, 3-imidazolidine-2-thiones and their derivatives are 
an interesting type of ligands, they possess ambidentate nature, may give a better result if 
they coordinate with platinum(II) ion.  They have been used for a long time as antifungal 
agents, protecting agent against nephritic side effects during cisplatin administration, and 
Figure 2.9 Chemical structure of a. carboplatin, b. oxaliplatin 
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as inhibitors of HIV-1 and HIV-2 reverse transcriptase [80].  The reactions of thione 
ligands with transition metals have been well studied in order to find simple model 
compounds for metalloproteins [81]. 
 
These ligands can coordinate to a metal through various modes, by their sulfur or nitrogen 
atoms. Also, they may exist in a thiol-thione equilibrium. Studies have displayed that the 
thione form is the dominant one in the solid state and in the most common solvents [82]. 
 
 
 
 
Figure 2.10 Tautomerism structure of Thiol - thione 
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CHAPTER 3 
EXPERIMENTAL WORK 
3.1 Materials and methods 
Cisplatin and transplatin were obtained from Fluka AG, bis(triethylphosphine) 
dichloridoplatinum(II) was purchased from STERM Chemicals, silver nitrate was obtained 
from MERCK Chemicals. The deuterated solvents and thione ligands were purchased from 
Sigma-Aldrich.  All other solvents were obtained from Fluka Chemical Co. And used 
without further purification. 
3.2 Synthesis of the complexes 
3.2.1  cis-[(Et3P)2PtL2]Cl2 complexes 
Complexes were synthesized in a same manner, through dropwise addition of a solution 
containing two equivalents of thione (1.00 mmol) dissolved in 10 ml methanol to 250 mg 
(0.50 mmol) of bis(triethylphophine)dichlorido platinum(II) dissolved in10 ml 
dichloromethane. The mixture was stirred for 3h resulting in a colored solution. The 
solutions were kept at room temperature after filtration, solid powders were obtained on 
slow evaporation of the solvent. 
Pt
Et3P
Et3P Cl
Cl
+ 2 L 
 
 
Cl2Pt
Et3P
Et3P L
L
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L = Imt; complex A1, (MeImt; A2), (Me2Imt; A3), (Et2Imt; A4), (Diaz; A5), (EtDiaz; 
A6), (Diap; A7). 
3.2.2 cis-[(NH3)2PtL2](NO3)2 complexes  
All compounds were prepared by adding (1.000 mmol) of AgNO3 to solutions containing 
(0.500 mmol) of cis-platin in 10 ml water and stirred for 24 hours in the dark at room 
temperature. The mixtures were filtered to remove the silver chloride precipitate. (0.500 
mmol) of thione ligands dissolved in 10 ml methanol were added dropwise to the filtrates, 
after stirring for 3 hours. The solutions was refiltered and the kept at room temperature. 
Solid powders were obtained on slow evaporation of the solvent. 
Pt
H3N
H3N Cl
Cl
+ 2AgNO3   
 
  
Pt 
H3N
H3N
OH2
OH2
+ 2AgCl(s)(NO3)2
 
 
Pt
H3N
H3N OH2
OH2
+ 2 L 
 
 
Pt 
H3N
H3N
L
L
(NO3)2(NO3)2 + 2 H2O
 
L = Imt; complex B1, (MeImt; B2), (Me2Imt; B3), (Et2Imt; B4), (PrImt; B5), (iPrImt; 
B6), (iPr2Imt; B7), (Diaz; B8), (EtDiaz; B9), (Diap; B10). 
3.2.3 Synthesis of trans-[Pt(NH3)2L2](NO3)2  complexes 
All compounds were prepared by adding (1.000 mmol) of AgNO3 to solutions containing 
(0.500 mmol) of trans-platin in 10 ml water and stirring for 24 hours in the dark at room 
temperature. The mixtures were filtered to remove the silver chloride precipitate. (0.500 
mmol) of thione ligands dissolved in 10 ml Methanol were added to the filtrates dropwise. 
The mixtures were stirred to give colored solutions. Filtration and room temperature 
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evaporations afforded powders. trans-[Pt(NH3)2(Imt)2](NO3)2 and trans-
[Pt(NH3)2(Me2Imt)2](NO3)2 complexes were crystallized from a mixture of methanol 
water. 
Pt
H3N
Cl NH3
Cl
+ 2AgNO3   
 
 
Pt 
H2O
H3N
NH3
OH2
+ 2 AgCl(s)(NO3)2
 
Pt
H3N
H2O NH3
OH2
+ 2 L Pt 
L
H3N
NH3
L
(NO3)2(NO3)2 + 2H2O
 
L = Imt; complex T1, (MeImt; T2), (Me2Imt; T3), (Et2Imt; T4), (PrImt; T5), (iPrImt; 
T6), (iPr2Imt; T7), (EtDiaz; T8), (Diap; T9). 
3.2.4 Synthesis of [PtL4](NO3)2 complex (C1)  
The compound was prepared by adding 168.8 mg (1.000 mmol) of AgNO3 to solution 
contain 150.06 mg (0.500 mmol) of cisplatin in 10 ml water. The mixture was stirred for 
24 hours in the dark at room temperature, then filtered. 288.2 mg (2.000 mmol) of N-
iPropyl-Imt dissolved in 10 ml Methanol was added to the filtrate. After stirring for 3 hours, 
the brown solution was filtered and kept at room temperature for evaporation to afford X-
ray quality crystals. 
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H3N Cl
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3.3 Spectroscopic measurements 
Melting points of the synthesized complexes were carried out on Electro thermal apparatus. 
Elemental analysis of carbon, hydrogen, nitrogen and sulfur were performed on Perkin 
Elmer Series 11(CHNS/O), Analyzer 2400. The solid state FTIR spectra of the ligands and 
their platinum(II) complexes were performed on a PerkineElmer FTIR180 
spectrophotometer using KBr pellets over the range 4000-400 cm-1 and solid Far-IR spectra 
below 400 cm-1 of the complexes were recorded at 4 cm-1  resolution at room temperature 
over polyethylene Disk. 
The 1H and 13C NMR spectra were carried out on a JEOL JNM-LA 500 NMR spectrometer 
at 500.00 MHz and 125.65 MHz operating frequency respectively. The spectra of 13C NMR 
were recorded at the above mentioned frequency with 1H broadband decoupling at 297 K. 
The conditions of the spectra were 32 K data points, 0.963 acquisition time, 3.2 s pulse 
delay and a 5.75µs pulse width for 1H NMR, and 32 K data points, 0.963 s acquisition time, 
2.5 s pulse delay and a 5.12µs pulse width for 13C NMR. The chemical shifts were 
measured relative to external reference TMS. 
The 13C solid state NMR spectra were performed on a JEOL LAMBDA 500 spectrometer 
at 125.65 MHz operating frequency corresponding to magnetic strength of 11.74 T, at 
ambient temperature. Samples were packed into 6mm zirconium oxide rotors. Cross 
polarization and high power decoupling were employed. Pulse delay of 7.0 s and a con- 
tact time of 5.0 ms were used in the CPMAS experiments. The magic angle spinning rates 
were from 2 kHz to 4 kHz. 13C chemical shift were referenced to TMS   by setting the high 
frequency isotropic peak of solid adamantine to 38.56 ppm. 
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3.4 Single crystal X-ray diffraction analysis 
X-ray data were collected at 173K (-100°C) on a Stoe Mark II-Image Plate Diffraction 
System  equipped with a two-circle goniometer and using MoK graphite monochromated 
radiation ( = 0.71073 Å). The structure was solved by direct methods with SHELXS-
2014/6. The refinement and all further calculations were carried by SHELXL-2014/6 [83].  
The N-bound and C-bound H-atoms were included in calculated positions and treated as 
riding atoms with N–H = 0.91 Å, C–H = 0.99 and 0.98 Å for CH2 and CH3 H atoms, 
respectively, and with Uiso(H) = 1.5Ueq(C) for methyl H atoms and = 1.2Ueq(N or C) for 
other H atoms [84]. The non–H atoms were refined anisotropically, using weighted full-
matrix least-squares on F2. A semi-empirical absorption correction was applied using the 
MULABS routine in PLATON [85]. The figures were drawn using the programs ORTEP 
[86] and MERCURY [86]. 
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Table 3.1 Crystallographic characteristics, experimental and structure refinement details 
of crystal structure of complexes (T1) and (T3) 
Parameter Complex T1 Complex T3 
Formula C6H18N8O6PtS2 C10H26 N8O6PtS2 
Formula weight 557.49 613.60 
Crystal size/mm 0.41 × 0.34 × 0.21 0.40 × 0.36 × 0.28 
Wavelength/Å 0.71073 0.71073 
Temperature/K 173 173 
Crystal symmetry Monoclinic Monoclinic 
Space group P 21/n P 21/n 
a/Å 5.4002 (4) 7.0160 (5) 
b/Å 23.4438 (15) 18.6235 (10) 
c/Å 6.6485 (5) 8.0794 (6) 
β/° 105.458 (6) 107.228 (6) 
V/ Å3 811.26 (10) 1008.31 (12) 
Z 2 2 
Dc/Mg m-3 2.282 2.021 
μ(Mo-Kα)/mm-1 8.95 7.21 
F(000) 536 600 
θ Limits/° 1.7–25.6 2.2–26.1 
Collected reflections 10466 13070 
Unique reflections(Rint) 1532 (0.087) 1900 (0.046) 
Observed reflections [Fo 
>2σ(Fo)] 
1332 1550 
Goodness of fit on F2 1.04 0.98 
R1(F), [I>2σ(I)] 0.023 0.015 
wR2 (F
2), [I>2σ(I)] 0.050 0.035 
Largest diff. peak, hole/e Å-3 0.99, −1.86 0.76 and −0.75 
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Table 3.2 Crystallographic characteristics, experimental and structure refinement details 
of crystal structure of complex C1. 
Parameter Compound 
CCDC deposit no. 1008031 
Empirical formula C24 H49.20 N10 O6.60 Pt S4 
Formula weight 906.86 
Temperature (K) 173 (2) 
Wavelength (Å) 0.71073 
Crystal system Tetragonal 
Space group P43212 
Unit cell dimensions  
a (Å) 11.608 (3) 
c (Å) 27.182 (1) 
Volume (Å3) 3662.7 (2) 
Z 4 
Calc. density (g.cm-3) 1.645 
Absorp. coefficient (mm-1) 4.11 
F(000) 1832 
Crystal size (mm) 0.45 × 0.35 × 0.20 
 range (o) 1.9–26.1 
Limiting indices -14 ≤ h ≤ 14 
 -14 ≤ k ≤ 13 
 -32 ≤ l ≤ 33 
Max and min transmission Tmin= 0.7681, Tmax= 1.0000 
Data/restraints/parameters 3457 / 5 / 230 
Goodness-of-fit on F2 0.875 
Final R indices [I >2 σ (I)] R1 = 0.0153, wR2 = 0.0265 
R indices (all data) R1 = 0.0259, wR2 = 0.0269 
Largest diff. Peak and hole (e Å-3) 0.34 and −0.75 
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3.5 In vitro cytotoxic activity against HeLa, A549, MCF7 and HTC15 
human cancer cell lines 
In the present study, metal precursor, cisplatin and seven synthesized complexes were 
evaluated for their in vitro cytotoxic activity against Hela (human cervical cancer), A549 
(human lung cancer), MCF-7 (human breast cancer) and HTC15 (human colon cancer) cell 
lines [87]. The cells were seeded at 4 x 103 cells/well in 100μL DMEM  containing 10% 
FBS in 96-wells tissue culture plate and incubated for 72 h at 37o C, 5% CO2 in air and 
90% relative humidity in CO2 incubator. After incubation, 100 μL of each sample solution 
(50, 25, 12.5 and 6.25 μM), prepared in DMEM, were added to cells and the cultures were 
incubated for 24 h.  The medium of wells was discarded and 100 μL DMEM containing 
MTT (3-(4, 5-Dimethylthiazol-2-Yl)-2, 5-Diphenyltetrazolium Bromide) (5 mg/mL) was 
added to the wells and incubated in CO2 incubator at 37
o C in dark for 4 h.  After incubation, 
a purple colored formazan (artificial chromogenic dye, product of the reduction of water 
insoluble tetrazolium salts e.g., MMT by dehydrogenases and reductases) in the cells is 
produced and appeared as dark crystals in the bottom of the wells.  
The medium of culture was discarded from each well carefully to prevent disruption of 
monolayer. 100 μL of DMSO was added in each well. The solution was thoroughly mixed 
to dissolve the formazan crystals, producing a purple solution. The absorbance of the 96-
wells plate was taken at 570 nm with Labsystems Multiskan EX-Enzyme-linked 
immunosorbent assay (EX-ELISA) reader against a reagent blank. The IC50 values were 
calculated from three independent experiments by generating an equation of logarithmic 
trendline of percentage cell viability against concentration compounds in Microsoft excel.  
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Figure 3.1 Percentage of Hela cell viability against compounds concentration 
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CHAPTER 4 
RESULTS AND DISCUSSIONS 
4.1 Synthesis and structures 
The reaction of the platinum(II) precursors with thione ligands afford a group of 
compounds with  general formula of cis-[(Et3P)2Pt(L)2]Cl2, cis-[(NH3)2Pt(L)2](NO3)2,  
trans-[Pt(NH3)2(L)2](NO3)2 and [Pt(iPrImt)4](NO3)2(0.6H2O)  in a good yields with 
different melting points. The observed elemental analytical data (CHNS)% of these 
complexes is consistent with their compositions as given below in table 4.1. 
 In order to characterize with the coordination mode of the thione ligand with Pt(II) center 
atom in these complexes, the structures of trans-[Pt(NH3)2(Imt)2](NO3)2, trans-
[Pt(NH3)2(Me2Imt)2](NO3)2 and [Pt(iPrImt)4](NO3)2, have been determined by X-ray 
crystallography.  
Table 4.1 Melting points and elemental analytical data for the synthesized complexes 
 
 
Species 
Chemical composition calculated & 
(found) % 
 
 
 
M.p(ºC) 
 
 
 
Color 
 
 
 
Yield % 
C H N S 
A1 
30.59 
(30.49) 
6.00 
(6.22) 
7.93 
(703.) 
9.07 
(8.61) 
223 - 225 White 89 
A2 
32.69            
(33.04) 
6.32                 
(6.18) 
7.63       
(8.11) 
8.73 
(8.11) 
246 - 250 White 82 
A3 
34.64           
(35.84) 
6.62                
(6.88) 
7.35             
(8.46) 
8.40 
(8.46) 
214 - 216 Yellow 69 
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A4 
38.13          
(37.99) 
7.15                      
)7.36) 
6.84     
(6.92) 
7.83                           
(8.08) 
189 - 191 Yellow 73 
A5 
32.56          
(33.04) 
6.30          
(6.96) 
7.60               
(7.63) 
8.69 
(8.46) 
208 - 210 Brown 84 
A6 
36.45 
(36.01) 
6.90 
(6.66) 
7.09 
(6.89) 
8.11 
(9.41) 
188 - 190 White 67 
A7 
34.64      
(35.22) 
6.62            
(7.96) 
7.35         
(7.40) 
8.41 
(8.24) 
159 - 161 Yellow 77 
 
T1 
B1 
12.92 
(13.45) 
(12.48) 
3.26 
(3.87) 
(3.56) 
20.10 
(21.29) 
(19.26) 
11.56 
(10.66) 
(12.37) 
- 
156 - 158 
130 - 132 
- 
White 
brown 
- 
92 
89 
 
T2 
B2 
16.40 
(15.86) 
(17.01) 
3.80 
(4.22) 
(3.78) 
19.14 
(17.15) 
(18.33) 
10.95 
(11.96) 
(13.06) 
- 
140 - 142 
 126 - 128 
- 
Beige 
yellow 
- 
80 
73 
 
T3 
B3 
19.57 
(20.07) 
(18.20) 
4.28 
(4.17) 
(4.80) 
18.26 
(16.89) 
(16.94) 
10.45 
(11.33) 
(10.72) 
- 
106 - 108 
73 -75 
- 
Beige 
Brown 
- 
81 
70 
 
T4 
B4 
25.10 
(24.07) 
(24.19) 
5.13 
(5.88) 
(5.08) 
16.73 
(17.62) 
(17.11) 
9.57 
(10.72) 
(10.23) 
- 
83 - 85 
111- 113 
- 
Yellow 
orange 
- 
67 
64 
 
T5 
B5 
22.43 
(20.99) 
(21.04) 
4.72 
(4.92) 
(4.88) 
17.45 
(16.60) 
(16.21) 
9.98 
(10.54) 
(10.07) 
- 
130 - 132 
125 - 127 
- 
White 
beige 
- 
77 
72 
 
T6 
B6 
22.43 
(21.05) 
(24.01) 
4.72 
(4.46) 
(4.95) 
17.45 
(15.65) 
(15.77) 
9.98 
(10.79) 
(9.68) 
- 
124 -126 
 138 - 140 
- 
Yellow 
white 
- 
73 
82 
 
T7 
B7 
29.78 
(28.55) 
(28.29) 
5.84 
(5.14) 
(5.82) 
15.44 
(15.43) 
(14.65) 
8.83 
(9.04) 
(9.87) 
- 
132 -134 
119 - 121 
- 
Orange 
Orange 
- 
58 
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 16.40 3.80 19.14 10.95 - - - 
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B8 (15.46) (4.33) (18.66) (11.96) 112 - 113 Orange 87 
 
T8 
B9 
22.43 
(22.70) 
(22.41) 
4.72 
(4.90) 
(4.42) 
17.45 
(16.58) 
(15.60) 
9.98 
(10.30) 
(11.04) 
- 
92 - 94 
86 - 88 
- 
Yellow 
Brown 
- 
71 
66 
 
T9 
B10 
19.57 
(21.96) 
(20.22) 
4.28 
(5.78) 
(4.50) 
18.26 
(16.38) 
(16.37) 
10.45 
(10.86) 
(9.49) 
- 
164 - 166 
155 - 157 
- 
Beige 
Brown 
- 
62 
80 
 
C1 
31.78 
(31.04) 
5.48 
(5.18) 
15.44 
(16.42) 
14.14 
13.97 
 
119 – 121 
 
Brown 
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4.1.1 Crystal structures of T1 and T3 complexes  
Suitable crystals of T1 and T3 were obtained as colorless blocks by slow evaporation of a 
mixture of water methanol. The molecular structures of the two complexes T1 and T3 are 
shown in (Fig 4.1 and Fig 4.3), respectively. The selected bond length and bond angles 
parameters are reported in (Table 4.2), Both structures are ionic, consisting of trans-
[Pt(NH3)2(Imt)2]
2+ and trans-[Pt(NH3)2(Me2Imt)2]
2+ cations and two uncoordinated nitrate 
ions. 
From the structures, Pt(II) ion is coordinated to two sulfur atoms of thione ligand and two 
N atoms of ammonia in a trans fashion. The Pt(II) ion is located in the inversion center in 
both structures and adopts nearly square-planar environment lying exactly within the plane 
defined by the two S and two N atoms. 
The cis angles around platinum vary between 87.50(9)° and 92.50(9)° in case of T1 and 
88.52(7)° and 91.48(7)° in case of T3, while the trans angles are 180° in both. In the 
structure of T1 The Pt–N and Pt–S bond distances are 2.046(3) and 2.3260(9)Ǻ 
respectively, while the distances are 2.054(2) and 2.3199(7)Ǻ respectively in T3 , these 
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values  are in agreement with the average of those reported for similar compounds [88]. 
Both thione ligands and ammonia molecules coordinated with the central Pt(II) ion are 
engaged in hydrogen bonding interactions with nitrate counter ions stabilizing the structure 
and leading to the formation of three-dimensional structure as shown In (Fig 4.2 & 4.4). 
Figure 4.1 Molecular structure of T1, showing atomic labeling. Displacement ellipsoids 
are drawn at the 50% probability level. Atoms not labelled are related by inversion 
symmetry 
Figure 4.2 Packing diagram of T1, along the c axis. The N–H…O, N–H…N and C–H…O 
hydrogen bonds are shown as dashed lines and lead to the formation of a 3D structure 
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Figure 4.4 Packing diagram of T3, along the c axis. The N–H…O, N–H…N and C–H…O 
hydrogen bonds are shown as dashed lines and lead to the formation of a 3D structure 
 
Figure 4.3 Molecular structure of T3, showing atomic labeling. Displacement ellipsoids 
are drawn at the 50% probability level. Atoms not labelled are related by inversion 
symmetry 
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Table 4.2 Selected bond angles (Å) and bond lengths (°) for complexes T1 & T3 
Bond Lengths (Å) 
Complex T1 Complex T3 
Pt1—N3 2.046 (3) Pt1—N3 2.054 (2) 
Pt1—S1 2.3260 (9) Pt1—S1 2.3199 (7) 
Bond Angles (°) 
Complex (T1) Complex (T3) 
N3—Pt1—S1 92.50 (9) N3—Pt1—S1 88.52 (7) 
N3i—Pt1—S1 87.50 (9) N3i—Pt1—S1 91.48 (7) 
N3i—Pt1—N3 180  N3i—Pt1—N3 180 
S1—Pt1—S1i 180 S1—Pt1—S1i 180 
Symmetry code (T1): (i) −x, −y, −z+1, Symmetry code (T3): (i) −x+1, −y, −z+1. 
 
Table 4.3 Hydrogen-bond geometry (Å, °) in complex T1 
D—H···A D—H H···A D···A D—H···A 
N1—H1N···O2ii 0.87 (2) 2.06 (3) 2.791 (4) 141 (4) 
N2—H2N···O3iii 0.86 (2) 2.13 (3) 2.882 (5) 146 (4) 
N3—H3CN···O1ii 0.87 (2) 2.31 (2) 3.149 (4) 163 (3) 
N3—H3CN···O2ii 0.87 (2) 2.55 (3) 3.270 (4) 140 (3) 
N3—H3AN···O1 0.88 (2) 2.15 (2) 3.001 (4) 162 (4) 
N3—H3BN···O1iv 0.88 (2) 2.18 (2) 3.044 (4) 167 (6) 
C3—H3A···O2v 0.99 2.60 3.362 (5) 134 
C3—H3B···O2vi 0.99 2.64 3.526 (4) 149 
Symmetry codes: (ii) x−1, y, z; (iii) x, y, z−1; (iv) −x+1, −y, −z+2; (v) x−1, y, z−1; (vi) 
x−1/2, −y+1/2, z−1/2. 
Table 4.4 Hydrogen-bond geometry (Å, °) in complex T3 
D—H···A D—H H···A D···A D—H···A 
N3—H3X···O2ii 0.91 2.08 2.956 (3) 161 
N3—H3Y···O1 0.91 2.22 3.034 (4) 148 
N3—H3Y···O3 0.91 2.43 3.258 (4) 152 
N3—H3Y···N4 0.91 2.69 3.561 (4) 160 
N3—H3Z···O1iii 0.91 2.11 2.944 (3) 151 
C2—H2B···O3iv 0.99 2.41 3.222 (4) 139 
C3—H3B···O2v 0.99 2.36 3.317 (4) 161 
C4—H4A···O3ii 0.98 2.51 3.470 (4) 168 
Symmetry codes: (ii) x+1, y, z; (iii) −x+1, −y, −z+2; (iv) x+1/2, −y−1/2, z−1/2; (v) x+1, y, 
z−1. 
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4.1.2  Crystal structure of complex C1  
The molecular structure of compound C1 is shown in (Fig 4.5) The Pt(II) ion is located on 
a two fold rotation axis and bound to the sulfur atoms of four N-isopropylimidazolidine-2-
thione (iPrImt) ligand molecules in a distorted square planar geometry. The Pt-S bond 
lengths are in the range 2.3035(8) - 2.3222(8) Å, while the S-Pt-S bond angles are in the 
range 89.34(4) - 92.17(4)°. The bond distances are similar to the related compound 
tetrakis(1-Methyl-4-imidazoline-2-thione) platinum(II) chloride dehydrate [29]. The SCN2 
moieties of the four ligand molecules are also essentially planar with the S-C and C-N bond 
lengths in the ranges (1.706(4) - 1.709(4)) Å and (1.321(4)-1.350(4) Å) respectively. 
However the geometry around the platinum ion exhibits interesting features. The structure 
presents a deviation from the ideal square planar geometry reminiscent of a bent seesaw 
distortion where the trans-sulfur atoms S1 and S1i are displaced above the [PtS4] mean 
plane by 0.2603(9) Å whereas S2 and S2ii are displaced below the mean plane by 0.2723(8) 
Å. A closer look to hydrogen bonding interactions reveals that the thione ligands of each 
of the two trans pairs are engaged in hydrogen bonding interactions with one oxygen atom 
from each nitrate counter ion, playing the role of a bridge between them: [N-H...ONO2…H-
N]. This H-bonding scheme gives rise to two decametallacycles [PtSCNH…O…HNCS] in 
which the trans sulfur atoms are pushed out of the [PtS4] mean plane and hence resulting 
in the minor seesaw distortionmean plane by 0.2603(9) Å whereas S2 and S2ii are displaced 
below the mean plane by 0.2723(8) Å. A closer look to hydrogen bonding interactions 
reveals that the thione ligands of each of the two trans pairs are engaged in hydrogen 
bonding interactions with one oxygen atom from each nitrate counter ion, playing the role 
of a bridge between them: [N-H...ONO2…H-N].    
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The hydration, water molecule and hydrogen atoms other N-H were omitted for clarity. 
(Pt1-S1, 2.3035(8) Å; Pt1-S2, 2.3222(8) Å; S1-Pt1-S2, 92.17(4)o; S1-Pt1-S2i, 89.34(4) o). 
Symmetry codes: i = y, x,-z; ii = -y+1/2, x-1/2, z-1/4; iii = x-1/2,-y+1/2,-z+1/4  
 
 
 
Figure 4.5 ORTEP diagram of complex C1, showing the atomic labeling scheme. 
Displacement ellipsoids are drawn at the 30 % probability level 
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4.2 Spectral measurements 
4.2.1 NMR studies 
1H and 13C NMR spectra of the cis-[ (Et3P)2Pt(L)2]Cl2 complexes have been measured in 
CDCl3 solution and spectra of the cis-[(NH3)2Pt(L)2](NO3)2 and  trans-
[Pt(NH3)2(L)2](NO3)2 complexes have been recorded in D2O and DMSO-d6. 
 All synthesized complexes show the expected signals.  Based on the symmetry of the solid 
state structures we should expect just a half number of peaks because of chemical 
environments similarity. All signals assigned to the free thione ligands observed in the 1H 
& 13C NMR spectra were also found in the Pt(II) complexes spectra. The N–H signals of 
all thione ligands become less intense upon complexation and shifted slightly downfield 
toward high frequency by 0.4 - 1.4 ppm from their positions in the free thione ligands. This 
shift is a good indication of the coordination of ligands to the platinum(II) center atom and 
the formation of the targeting compounds. The N–H proton deshielding is related to an 
increase of the π electron density in the C–N bond upon coordination, which indicates that 
the ligands were coordinated to the centers of platinum(II)  through the sulfur atom and not 
via nitrogen [89]. 
The 13C NMR chemical shifts of the free ligands and their Pt(II) complexes are listed in 
(Table 4.5 & Table 4.6). In all platinum(II) compounds, the C-2 signals, corresponding to 
thiocarbonyl C=S resonance appear (upfield) in the lower frequency regions by 2.0 - 14 
ppm as compared to the free thiones. This shift was attributed to the decreasing bond order 
of a C=S upon complexation which leads to a shift of the electron density, and formation 
a partial double bond character in the C–N bond. This clearly supports the fact that  thiones 
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are bonding through sulfur [90]. The difference in the thiocarbonyl resonance  shift may 
be related to the platinum–sulfur bond strength as noticed in the other platinum(II) 
complexes of thiones [81]. 
Table 4.5 1H, 13C NMR chemical shifts of the free Ligands and their complexes in CDCl3. 
Species N-H C-2 C-4 C-5 C-6 C-7 N-C1 N-C2 P-C1 P-C2 
Imt 7.98 182.11 45.38 45.38 - - - - - - 
A1 9.19 174.50 46.60 46.60 - - - - 9.30 14.96 
MeImt 7.93 181.38 42.00 51.82 - - 34.35 - - - 
A2 8.65 174.32 42.56 52.13 - - 34.47 - 7.93 13.52 
Me2Imt - 180.46 48.73 48.73 - - 34.80 - - - 
A3 - 174.33 49.71 49.71 - - 35.16 - 7.89 13.58 
Et2Imt - 178.74 46.13 46.13 - - 42.69 11.92 - - 
A4 - 171.94 47.38 47.38 - - 43.77 12.08 8.84 12.08 
Diaz 7.77 173.34 38.36 19.29 38.36 19.29 - - - - 
A5 9.13 166.68 41.53 19.92 41.53 19.92 - - 8.83 14.37 
Et-Diaz 7.70 173.36 41.14 20.93 46.14  49.54 12.33 - - 
A6 8.32 168.24 41.35 20.91 47.03  49.66 12.43 8.08 13.33 
Diap 7.70 183.99 45.86 26.70 45.86 26.70 - - - - 
A7 8.50 175.22 46.44 26.46 46.44 26.46 - - 7.88 13.50 
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Table 4.6 1H and 13C chemical shifts (ppm) for the free Ligands and their Pt(II) 
complexes in DMSO-d6, and D2O  
Species  N–H C-2 C-4 C-5 C-6 C-7 N-C1 N-C2, N-C3 
Imt 7.98 182.11 45.38 45.38 - - - - 
B1  9.04 174.89 45.96 45.96 - - - - 
T1 9.09 175.74 45.76 45.76 - - - - 
MeImt 7.93 181.38 42.00 51.82 - - 34.35 - 
B2 8.82 173.92 42.88 52.50 - - 34.07 - 
T2 8.47 174.90 42.76 52.65 - - 34.02 - 
Me2Imt - 180.46 48.73 48.73 - - 34.80 - 
B3 - 172.35 49.75 49.75 - - 35.80 - 
T3 - 166.89 50.29 50.29 - - 36.07  
Et2Imt - 178.74 46.13 46.13 - - 42.69 11.92 
B4 - 171.02 47.45 47.45 - - 43.78 12.16 
T4 - 170.96 47.33 47.33 - - 43.79 12.11 
PrImt 7.99 180.87 49.14 48.86   42.11 20.65, 11.09 
B5 8.63 169.74 50.02 48.92 -  42.97 20.64, 10.95 
T5 8.81 174.50 50.10 49.10 -  42.82 20.53, 10.95 
i-PrImt 7.96 179.70 42.21 43.73 - - 48.18 19.55 
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B6 8.57 172.60 42.94 44.69 - - 48.90 19.23 
T6 8.31 174.11 44.05 42.42   48.88 19.18 
C1 8.77 174.17 44.65 42.71   48.78 19.20 
i-Pr2Imt - 171.05 48.25 48.25 - - 41.52 19.10 
B7 - 165.55 48.86 48.86 - - 41.22 18.94 
T7 - 169.42 42.30 42.30   49.68 19.26 
Diaz 7.77 173.34 41.00 19.25 41.00 - - - 
B8 8.83 166.78 41.03 18.86 41.03 - - - 
EtDiaz 7.70 173.36 41.14 20.93 46.14 - 49.54 12.33 
B9 8.44 165.54 41.38 20.31 47.53 - 49.61 12.51 
T8 8.32 167.43 47.32 20.27 41.09 - 49.67 12.19 
Diap 7.70 183.99 45.86 26.99 26.99 45.86 - - 
B10 8.74 177.29 47.40 26.70 26.70 47.40 - - 
T9 8.70 176.53 46.35 26.51 26.51 46.35 - - 
 
The 31P solution NMR spectra of (A1-A7) complexes have been carried out in CDCl3 
solution. For these complexes three resonances with relative integral values of 1:4:1 around 
9.0 ppm, as shown in appendix B. With both active and inactive spins platinum isotopes 
present, the 31P NMR spectra will consist of signals with intensities corresponding to the 
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natural abundance of each isotope. Active 195Pt (I = ½) has a natural abundance of 33.8%, 
while the remaining isotopes are inactive.  So the singlet signal resonance peaks, arising 
from 31P nuclei adjacent to platinum inactive isotopes [91], in contrast  the two peaks with 
ratio 1:1 signals is assigned as  doublet due to presence of heteronucelar coupling between 
31P – 195Pt with high spin coupling constant 1J 195Pt - 31P, This high spin coupling constant 
is probably due to a high covalency of the platinum-phosphorus bond, which is in 
agreement with the values reported in the literature for the bisphosphine in the classic 
example of square-planar platinum(II) complexes  between 1462 and 5698 Hz  [92]. 
The slight down field shifts was observed in the all synthesized complexes in compared to 
the precursor, this shift is likely due to back donation from platinum d-orbital to the empty 
π* orbital of  the thiocarbonyl , which is known to as strong π-accepting ligand [93], leading 
the lone pair of phosphorus move toward the platinum [94]. 
Table 4.7 31P NMR chemical shift of the precursor and synthesized complexes in CDCl3 
Species ∂ ppm 1J(195Pt-31P ), Hz 
Precursor s, 7.2 . d, 8.6 2932 
A1 s, 9.2 , d, 9.2 2244 
A2 s, 9.1 . d,  8.9 2559 
A3 s, 9.2 . d, 9.0 2358 
A4 s, 8.9 . d, 9.0 2658 
A5 s, 9.2 . d, 9.2 2278 
A6 s, 9.3 . d, 9.4 2547 
A7 s, 8.7 . d 8.6 2300  
The shifts were measured relatively to external phosphoric acid (0 ppm) reference. 
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It was noticed that by increasing of the thione ligands ring size from five membered ring 
to six and seven (Imt, Diaz and Diap) the hetero nuclear coupling constant between 31P – 
195Pt increased, a possible explanation of this is that a big rings have less s-character gaining 
lesser share of the platinum 6s orbital, thus increasing P – Pt bond covalancy leading to the 
increase in the coupling constant value as you can see in the below figure 
 
4.2.2 Solid State 13C NMR 
Solid state 13C NMR data of the complexes are given in table 10.  Thiocarbonyl resonances 
in the free thione ligands, Imt, MeImt, Me2Imt, Et2Imt, PrImt, iPrImt, Diaz, EtDiaz, Diap 
appear at 180.6, 181.4, 181.4, 180.1, 180.1, 180.8, 175.6, 176.2, 188.4 ppm respectively, 
as reported in the literature [82]. Upfield shifts by about 2.4 to 12.59 ppm relative to the 
Figure 4.6 Graph shows the relationship between the ligands ring size and hetero nuclear 
195 Pt-31P coupling constant  
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free ligand were observed upon complexation of Pt(II) with the thiones [95]. This is 
consistent with thione ligand coordination through sulfur atom and also confirm that thione 
form is dominant after complexation.  
Table 4.8 13C solid state NMR chemical shifts (ppm) of the free Ligands and their 
platinum(II) complexes  
Species C-2 C-4 C-5 C-6 C-7 N-C1 N-C2 N-C3 P-C1 P-C2 
A1 171.50 44.66 44.66 - - - - - 16.31 12.05 
A5 169.42 45.70 20.44 45.70 20.44 - - - 16.34 13.17 
A7 175.81 51.57 30.57 51.57 30.57 - - - 17.88 13.17 
T1 172.78 50.05 50.05 - - - - - - - 
T2 177.92 47.76 56.4 - - 39.31  - - - 
T3 172.72 52.43 52.43 - - 38.95  - - - 
T4 174.64 50.04 50.04 - - 46.36 14.85 - - - 
T5 176.15 74.11 52.50 - - 52.50 23.42 16.03 - - 
T6 176.47 46.91 46.91 - - 50.57 22.29 - - - 
T8 173.13 43.90 22.00 49.53 - 49.53 15.45 - - - 
T9 178.18 50.94 31.47 50.94 31.47 - - - - - 
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Table 4.9 1H NMR chemical shift of the free ligand and their complexes 
Species H-4 H-5 H-6 H-7 N-C1 N-C2 N-C3 P-C1 P-C2 
Imt s,4H,3.59 s, 4H,3.59 - - - - - -  
A1 s,4H,3.85 s,4H,3.85 - - - - - q,12H,2.03 t,18H,1.13 
B1 s,4H,3.68 s, 4H,3.68 - - - - - - - 
T1 s,4H,3.69 s, 4H,3.69 - - - - - - - 
MeImt t,2H,3.63 t,2H,3.43 - - s,3H,2.92 - - - - 
A2 t,2H,3.77 t,2H,3.77 - - s,3H,2.96 - - q,12H,2.06 t,18H,1.15 
B2 t,2H,3.75 t,2H,3.58 - - s,3H,2.98 - - - - 
T2 t,2H,3.71 t,2H,3.56 - - s,3H,2.96 - - - - 
Me2Imt s,4H,3.48 s, 4H,3.48 - - s,6H,2.91 - - - - 
A3 s,4H,3.55 s, 4H,3.55 - - s,6H,3.01 - - q,12H,2.02 t,18H,1.11 
B3 s,4H,3.67 s, 4H,3.67 - - s,6H,3.18 - - - - 
T3 s,4H,3.65 s, 4H,3.65 - - s,6H,3.29 - - - - 
Et2Imt s,4H,3.48 s,4H,3.48 - - q,4H,3.37 t,6H,0.97 - - - 
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A4 s,4H,3.52 s,4H,3.52 - - q,4H,3.51 t,6H,1.08 - q,12H,1.98 t,18H,1.08 
B4 s,4H,3.48 s,4H,3.48 - - q,4H,3.37 t,6H,0.97 - - - 
T4 s,4H,3.48 s,4H,3.48 - - q,4H,3.37 t,6H,0.97 - - - 
PrImt t,2H,3.58 t,2H,3.41 - - t,2H,3.31 m,2H,1.45 t,3H,0.73 - - 
B5 t,2H,3.73 t,2H,3.59 - - t,2H,3.36 m,2H,1.52 t,3H,0.76 - - 
T5 t,2H,3.76 t,2H,3.62 - - t,2H,3.35 m,2H,1.55 t,3H,0.79 - - 
i-PrImt t,2H,3.53 t,2H,3.38 - - m,1H,4.35 d,6H,1.00 - - - 
B6 t,2H,3.68 t,2H, 3.57 - - m,1H,4.30 d,6H,1.06 - - - 
T6 t,2H,3.70 t,2H, 3.54 - - m,1H,4.25 d,6H,1.07 - - - 
i-Pr2Imt s,4H,3.22 s, 4H,3.22 - - m,1H,4.48 d,6H,0.99 - - - 
B7 s,4H,3.41 s, 4H,3.41 - - m,1H,4.46 d,6H,0.99 - - - 
T7 s,4H,3.49 s, 4H,3.49 - - m,1H,5.10 d,6H,1.05 - - - 
Diaz t,4H,3.15 m,2H,1.75 t,4H,3.15 - - - - - - 
A5 t,4H,3.60 m,2H,1.67 t,4H,3.60 - - -  q,12H,2.12 t,18H,1.21 
B8 4H, 3.2 m,2H,1.74 4H, 3.2 - - - - - - 
52 
 
EtDiaz t,2H,3.62 m,2H,1.83 t,2H,3.28 - q, 2H,3.12 t, 3H,1.02 - - - 
A6 t,2H,3.68 m,2H,1.93 t,2H,3.36 - q,2H,3.26 t,3H,1.12  q,12H,2.02 t,18H,1.18 
B9 t,2H,3.56 m,2H,1.85 t,2H,3.34 - q, 2H,3.27 t, 3H,1.05 - - - 
T8 t,2H,3.59 m,2H,1.84 t,2H,3.33 - q, 2H,3.21 t, 3H,1.09  - - 
Diap t,4H,1.67 t,4H,3.18 t,4H,3.18 t,4H,1.67 - - - - - 
A7 t,4H,1.78 t,4H,3.51 t,4H,3.51 t,4H,1.78 - - - q,12H,2.04 t,18H,1.10 
B10 t,4H,1.62 t,4H,3.20 t,4H,3.20 t,4H,1.62 - - - - - 
T9 t,4H,1.70 t,4H,3.24 t,4H,3.24 t,4H,1.70 - - - - - 
      s: singlet, d: doublet, t: triplet, q: quar
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4.2.3 FT-IR spectroscopy 
Selected Infrared spectroscopic absorption frequency of the free thione ligands and their 
corresponding platinum(II) compounds are stated in (Table 4.10). A characteristic band in 
the spectrum of the free thiones near 3200 cm−1 was observed and assigned to N–H 
stretching vibrations. This band is shifted to a higher frequency in all platinum (II) 
complexes due to an increase in the double bond character of C-N. This confirms that the 
thione ligand coordinates to the platinum(II) ion through sulfur of thiocarbonyl group [89]. 
The presence of (N–H) vibration bands in the complexes consistent with the presence of 
solid state thione form in the complexes [96]. Another important vibrational band is due to 
the thiocarbonyl group. This group is less polar than the carbonyl group C=O and has a 
considerably weak band at lower frequency 1250 – 1020 cm-1 this band difficult to identify 
[97]. In addition, several other bands in the broad region   of 1560 – 700 cm-1, are attributed 
to the strong coupling of C=S stretching with C-N stretching and other vibrational modes 
[97, 98].  
In all, free ligands the band around 1200 cm−1, could be assigned to ν(C=S) stretching 
vibration based on the reported values in the literature [99]. The shifting of bands towards 
lower wave number in most platinum(II) complexes, is in agreement with our suggestion 
that sulfur atom is bonded to platinum center and the double bond character has been 
reduced. A band around 825 cm-1 was observed for the cis-[Pt(NH3)2(L)2](NO3)2 and trans-
[Pt(NH3)2(L)2](NO3)2 series and does not appear in the free ligands and cis-
[(Et3P)2Pt(L)2)]Cl2 series, this band is attributed to NO3
-  bending and is an indication that 
NO3
- doesn’t coordinate [100].  
54 
 
The far-infrared spectra in the frequency region below 400 cm-1 has been recorded to 
investigate metal–sulfur  Pt-S) and metal–phosphorus Pt-P) stretching frequencies,  
which lie at  about 300 cm-1 for the transition-metal complexes according to literature 
[101]. In all complexes a sharp peak around 270 cm-1 was observed and assigned to 
platinum-sulfur bond. In case of the first series another peak around 300 cm-1 were 
observed and assigned for Pt-P bond.  
Table 4.10 IR absorption bands (cm-1) assignments for free ligands and their complexes 
 
Species 
IR Frequency (cm-1) 
CS)  (NO3-) Pt-S) Pt-P) 
Imt 1199 3200 - - - 
A1 1034 3446 - 272 305 
T1 1042 3310 836 272 - 
B1 1036 3376 827 273 - 
MeImt 1200 3200 - - - 
A2 1052 3418 - 280 299 
T2 1112 3528 837 274 - 
B2 1028 3481 823 287 - 
Me2Imt 1201 - - - - 
A3 1048 - - 281 307 
T3 1118 - 825 265 - 
B3 1114 3452 825 280 - 
Et2Imt 1199 - - - - 
A4 1088 - - 279 311 
55 
 
T4 1065 - 826 284 - 
B4 1079 - 837 268 - 
PrImt 1201 3210 - - - 
T5 1033 3373 824 282 - 
B5 1026 3429 827 282 - 
i-PrImt 1193 3210 - - - 
T6 1064 3566 867 279 - 
B6 1062 3550 824 274 - 
C1 1076 3209 844 269 - 
i-Pr2Imt 1198 - - - - 
T7 1106 - 856 283 - 
B7 1036 - 840 283 - 
Diaz 1206 3200 - - - 
A5 1043 3422 - 282 309 
B8 1070 3459 811 268 - 
EtDiaz 1217 3210 - - - 
A6 1038 3448 - 274 303 
T8 1074 3446 835 279 - 
B9 1039 3465 824 291 - 
Diap 1190 3224 - - - 
A7 1034 3521 - 267 306 
T9 1053 3270 822 269 - 
B10 1002 3490 808 276 - 
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4.3 In vitro cytotoxicity of cis-[(Et3P)2Pt(thione)2]Cl2 compounds against a 
panel of human cancer cell lines 
in vitro cytotoxicity of the compounds A1- A7 were evaluated against four human cancer 
cell lines [102], HeLa,  A549, MCF7,  and HCT15 cell lines [103, 104]. The exposure of 
the cells to the increase in the concentrations of the complexes resulted in a dose dependent 
cytotoxic effect. This was obtained by the stipulated increase in the concentrations of the 
compounds against different number of human cancer cells. The IC50 concentration of the 
complexes was obtained from curves between the complexes concentration and percentage 
viability of the cells. The IC50 values of the complexes ranged between 1.2 and 37 µM as 
given in (Table 4.11).  
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Figure 4.7 Graph showing complexes concentration effect on viability of Hela cell 
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Figure 4.8 Graph showing complexes concentration effect on viability of A549 cell 
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Figure 4.9 Graph showing complexes concentration effect on viability of MCF7 cell 
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Figure 4.10 Graph showing complexes concentration effect on viability of HCT15 cell 
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Table 4.11 IC50 Values in (µM) of compounds A1-A7, against four human tumor cell lines 
IC50 ± SEMa 
Compounds HeLa A549 MCF7 HCT15 
Cisplatin 16.1 ± 1 30.1 ± 1 24 ± 1 17 ±1 
Carboplatin 56 ± 2 71 ± 3 64 ± 2 56 ± 2 
Precursor 46 ± 2 56 ±2 39 ± 2 60 ± 2 
A1 1.4 ± 0.3 3.5 ±0.7 7 ± 1 4.7 ± 1 
A2 1.8 ± 0.3 3.9 ±0.5 8.6 ±0.9 2.6 ± 0.9 
A3 1.5 ± 0.2 2.4 ± 0.3 4.2 ± 0.7 3.8 ± 0.6 
A4 10 ± 2 13 ± 1 16 ± 1 14 ± 1 
A5 2.2 ± 0.5 4.5 ± 0.8 6.9 ± 1 4.7 ± 1 
A6 1.8 ± 0.4 3.6 ± 0.7 5.7 ± 0.9 1.2 ± 0.3 
A7 17 ± 1 28 ± 1 37 ± 2 22 ± 1 
The experimental results are presented as micro-mole concentration of 50% cell growth 
inhibition (IC50) of each drugs. The MTT assay was performed in three independent 
experiments, each in triplicate. 
aErrors are standard deviations determined from at least three independent experiments. 
 
The IC50 data in the above table, demonstrated higher cytotoxic activity for our synthesized 
complexes. Interestingly, all complexes displayed superior cytotoxic effects against Hela 
cell line, by a factor of 32 to 40 and 27 to 32 higher than carboplatin and the precursor 
respectively. Complexes A1 - A6 were showed 1.6 to 11 times higher activity even than 
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cisplatin in the same cell, with IC50 in the range of 1.0 - 10 µM, while the last complex A7 
showed slightly lower cytotoxicity with respect to cisplatin . 
For A549 cell; all complexes demonstrated inhibition of the cell growth and showed 
promising cytotoxic activity. The results showed the complexes have 1.1 to 9.0 time’s 
higher cytotoxicity than cisplatin, 20 to 26 fold higher than carboplatin and 16 to 20 fold 
higher than the precursor. 
The MTT results showed the effect of the complexes A1 – A6 on human breast cancer cell, 
the IC50 values, in the range of 4.2 – 12 µM, indicate that the complexes are stronger in 
vitro cytotoxic agents than that of carboplatin, precursor and cisplatin, while the complex 
A7 was recognized to be less cytotoxic than cisplatin with IC50 value of 37 µM, and still 
with higher cytotoxicity than carboplatin and the precursor. 
These complexes were also evaluated against human colon cancer cell line, the complexes 
A1 –A6 showed significant cytotoxicity and found to be 1.3 to 14, 4 to 45 and 4.4 to 49 
fold higher cytotoxicity than cisplatin, carboplatin and the precursor respectively. Only 
complex A7 was found to be less cytotoxic than the parent drug cisplatin, although it’s 
more cytotoxic than carboplatin and the precursor. 
The obtained results demonstrate that the cytotoxicity enhances dramatically toward the 
synthesized compounds. A1 – A5 have high cytotoxicity against the HeLa cell line [1.4 – 
9.9] μM, while A6 was found to be the most effective complex with IC50 value of 1.2 μM 
against HCT15 and 14 fold better than cisplatin. These results are consistent with a 
significant selective cytotoxicity of our complexes against particular cancer cell lines and 
their tendency to undergo ligand exchange with biomolecules like proteins and DNA. 
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Even though the exact mechanism on cytotoxicity of these complexes remains 
inconspicuous, the lowest cytotoxicity of complex A7 compared to the others, likely due 
to the ring size of the Diap ligand.
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CHAPTER 5 
CONCLUSION & RECOMMENDATIONS 
Three new series of platinum(II) complexes with general formula cis-[ (Et3P)2Pt(L)2]Cl2 , 
cis-[(NH3)2Pt(L)2](NO3)2 and  trans-[Pt(NH3)2(L)2](NO3)2 have been successfully 
synthesized and characterized using both analytical and spectroscopic techniques. The 
NMR and elemental analysis data strongly support the formation of the products. 
In order to characterize the coordination mode of the thione ligand with platinum(II) center 
ion in these complexes, the structure of trans-[Pt(NH3)2(Imt)2](NO3)2 and trans-
[Pt(NH3)2(Me2Imt)2](NO3)2, in addition to [Pt(iPr-Imt)4](NO3)2  have been determined by 
X-ray crystallography. The data confirmed that the Pt(II) ion is bonded to the thione ligands 
through their sulfur atoms. Hydrogen bonding interactions in compound C1 induce a bent 
see-saw distortion, relative to the ideal square planar geometry.  
In vitro cytotoxicity studies demonstrated a significant activity of the synthesized 
complexes against the selected cell lines; cis-[(Et3P)2Pt(Et-Diaz)2]Cl2 complexes was 
found to be the  most effective and 14 times better cytotoxic agent than cisplatin against 
human colon cancer (HCT15). The rest of the synthesized compound should evaluate in 
vitro cytotoxic activity. For further studies we recommend to study the interaction of these 
compounds with DNA as well as the electronic effect of the ligand.
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Appendix A 
1H NMR 
1H NMR Chemical shift (ppm) of the free Imt ligand and its platinum(II) complexes in DMSO–d6 
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1H NMR Chemical shift (ppm) of the free Diaz ligand and its platinum(II) complexes in DMSO–d6 
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1H NMR Chemical shift (ppm) of the free Diap ligand and its platinum(II) complexes in DMSO–d6 
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Appendix B 
31P solution NMR 
31P Chemical shift (ppm) of the precursor and three platinum(II) complexes in CDCl3 
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Appendix C 
13C solution NMR 
13C Chemical shift (ppm) of the free Imt ligand and its platinum(II) complexes in D2O 
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13C Chemical shift (ppm) of the free MeImt ligand and its platinum(II) complexes in D2O 
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13C Chemical shift (ppm) of the free Me2Imt ligand and its platinum(II) complexes in D2O 
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13C Chemical shift (ppm) of the free Et2Imt ligand and its platinum(II) complexes in D2O 
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13C Chemical shift (ppm) of the free PrImt ligand and its platinum(II) complexes in D2O 
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13C Chemical shift(ppm) of the free iPrImt ligand and its platinum(II) complexes in D2O 
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13C Chemical shift (ppm) of the free Diaz ligand and its platinum(II) complexes in D2O 
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13C Chemical shift (ppm) of the free EtDiaz ligand and its platinum(II) complexes in D2O 
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13C Chemical shift (ppm) of the free Diap ligand and its platinum(II) complexes in D2O
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Appendix D 
13C solid state NMR 
13C Chemical shift (ppm) of the free N-MeImt ligand and its trans platinum(II) complex 
                                      * Spinning side band 
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13C Chemical shift (ppm) of the free N,N-Me2Imt ligand and its trans platinum(II) complex 
                                   * Spinning side band 
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13C Chemical shift (ppm) of the free N-PrImt ligand and its trans platinum(II) complex 
                                       * Spinning side band 
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13C Chemical shift (ppm) of the free EtDiaz ligand and its trans platinum(II) complex 
                                        * Spinning side band
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